Ivacaftor (hydrate)

Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.

Product Specifications

CAS Number

[1134822-07-3]

Product Name Alternative

VX-770 hydrate

UNSPSC

12352005

Target

Autophagy; CFTR

Type

Reference compound

Related Pathways

Autophagy; Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/ivacaftor-hydrate.html

Solubility

10 mM in DMSO

Smiles

CC(C)(C1=C(C=C(C(C(C)(C)C)=C1)O)NC(C2=CNC3=C(C2=O)C=CC=C3)=O)C.O

Molecular Formula

C24H30N2O4

Molecular Weight

410.51

References & Citations

[1]Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770) . Hepatology. 2017 Feb;65 (2) :560-570|[2]Mutyam V, et al. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation. J Cyst Fibros. 2017 Jan;16 (1) :24-29|[3]Hadida S, et al. Discovery of N- (2,4-di-tert-butyl-5-hydroxyphenyl) -4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J Med Chem. 2014 Dec 11;57 (23) :9776-9|[4]Van Goor F, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106 (44) :18825-30.